KROS
HealthcareKeros Therapeutics, Inc.
$17.92
$-0.62 (-3.34%)
Jan 5, 2026
Price History (1Y)
Analysis
Keros Therapeutics, Inc. is a biotechnology company listed in the healthcare sector with a market capitalization of $545.95M. The company operates within the industry and has a significant scale, employing 82 individuals. Additionally, its revenue for the trailing twelve months (TTM) stands at $246.72M. The company's financial health is characterized by several key metrics. Keros Therapeutics' profitability margins are notable, with a gross margin of 37.2%, but a negative operating margin of -107.9%. The profit margin stands at 26.1%. Returns on equity and assets are reported as 10.4% and 4.4%, respectively. The company's balance sheet shows $693.47M in cash and $17.43M in debt, resulting in a debt-to-equity ratio of 2.48. A current ratio of 29.86 indicates that the company has sufficient liquidity. Keros Therapeutics' valuation metrics include a price-to-earnings (P/E) ratio of 11.87 on a TTM basis and -6.09 on a forward-looking basis, suggesting some volatility in earnings expectations. The revenue growth rate from year-over-year (YoY) is significant at 3575.8%, although the earnings growth rate for the same period is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $545.95M
- P/E Ratio
- 11.87
- 52-Week High
- $22.55
- 52-Week Low
- $9.12
- Avg Volume
- 1.04M
- Beta
- 0.90
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 82